Alexion’s Ultomiris Expands Its Reach As Soliris Biosimilars Loom
Executive Summary
The US firm’s Ultomiris reduced the risk of relapse in a late-stage trial for the serious autoimmune disease NMOSD, triggering plans for a label expansion to yet another indication currently dominated by its older product Soliris.